In two studies, researchers sequenced nearly 500 tumors to uncover hallmarks of aggressive prostate cancer.
A team led by University of Toronto researchers developed the signature as a clinical assay that could predict treatment response.
Based on the results, the researchers, based in Toronto, have initiated a clinical study in Ontario, called OCTANE, that involves a number of cancer centers in the province.
Results from a recent study clarify some conflicting prior determinations, and provide a new rationale to further explore the FCGR2A biomarker in prospective trials.
The initial phase of GENIE, which stands for Genomics, Evidence, Neoplasia, Information, Exchange, involves seven founding members and two informatics partners.
Canada's Hospital for Sick Children and the University Health Network's Princess Margaret Cancer Centre are piloting a new IT infrastructure for analyzing genetic and other kinds of biomedical data.
This story has been updated to include additional information from a US survey on people's attitudes about cost of genetic testing. Originally published June 4.
By a GenomeWeb staff reporter
OICR plans to validate the machine and develop a framework for sequencing patient tumors that can help physicians make informed decisions about treatments or clinical trial placements.
The company's most recent deal to apply its technology for assay development is "part of a broad program we have embarked on to exploit our unique ability to apply mass spectrometry to FFPE tissue," a company official said.
In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.
Technology Review points out that a new US presidential science advisor hasn't been selected.
Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.
President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.